Filtered By:
Drug: Atorvastatin Calcium

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 101 results found since Jan 2013.

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
Clinical scenario Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors which reduce the risk of coronary events and death by lowering blood concentrations of low density lipoprotein cholesterol (LDL-c).1,2,3,4 They are generally regarded as safe and well tolerated. However, some patients experience adverse muscle symptoms; these are mostly relatively mild but, in rare cases, severe muscle damage with renal failure (rhabdomyolysis) may occur (reviewed in 5,6). Recently, an autoimmune form of necrotising myositis has also been identified as a rare statin-associated myopathy (reviewed in 7). There ...
Source: PLOS Currents Evidence on Genomic Tests - December 4, 2013 Category: Genetics & Stem Cells Authors: Alison Stewart Source Type: research

Inclusion Body Myositis (IBM) and HMG CoA Reductase Antibody Myopathy: A Rare Case (P3.127)
CONCLUSION: In patients with IBM and abrupt worsening, secondary causes of myopathy should be considered. In patients with a history of statin exposure, HMG CoA reductase antibody myopathy should be included in the evaluation as it is potentially treatable with immune therapy.Disclosure: Dr. Kulhari has nothing to disclose. Dr. Preston has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kulhari, A., Preston, D. Tags: Acquired Muscle Disorders: Clinical and Pathological Aspects Source Type: research

Drug –Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data
ConclusionsReports of myopathy were not disproportionally higher among those using SGLT-2i with statins compared to SGLT-2i or statins alone at the class level. Further observational studies may be needed to better assess this interaction at the agent level.
Source: Drug Safety - March 5, 2022 Category: Drugs & Pharmacology Source Type: research

Elucidation of the Mechanism of Atorvastatin-Induced Myopathy in a Rat Model.
Abstract Myopathy is among the well documented and the most disturbing adverse effects of statins. The underlying mechanism is still unknown. Mitochondrial dysfunction related to coenzyme Q10 decline is one of the proposed theories. The present study aimed to investigate the mechanism of atorvastatin-induced myopathy in rats. In addition, the mechanism of the coenzyme Q10 protection was investigated with special focus of mitochondrial alterations. Sprague-Dawely rats were treated orally either with atorvastatin (100mg/kg) or atorvastatin and coenzyme Q10 (100mg/kg). Myopathy was assessed by measuring serum creatin...
Source: Toxicology - June 22, 2016 Category: Toxicology Authors: El-Ganainy SO, El-Mallah A, Abdallah D, Khattab MM, El-Din MM, El-Khatib AS Tags: Toxicology Source Type: research

Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
CONCLUSION: Our results clearly demonstrate that the frequency of CYP3A5*3 splicing variant is higher in myopathy group than in the tolerant group. We did not find significant association of genetic polymorphisms in CYP3A5, COQ, and SLCO1B1 with atorvastatin- or rosuvastatin-induced myopathy. PMID: 30595243 [PubMed - in process]
Source: Indian Heart J - December 1, 2018 Category: Cardiology Authors: Ramakumari N, Indumathi B, Katkam SK, Kutala VK Tags: Indian Heart J Source Type: research

Statin Induced Necrotizing Autoimmune Myopathy: An uncommon complication of a commonly used medication
We report a case of statin induced necrotizing autoimmune myopathy (SINAM), a rare variant of statin-induced myopathy.A 64-year-old gentleman on atorvastatin presented with muscle weakness, initial laboratory results showed elevated liver function tests, a creatine phosphokinase (CPK) of 8200 IU/L and positive urine myoglobin. Despite discontinuing atorvastatin, his CPK remained persistently elevated. Muscle biopsy was consistent with necrotizing myopathy. Anti - HMG CoA reductase antibody was strongly positive. Steroids followed by intravenous immunoglobulin were given. His muscle weakness, CPK, and liver functions gradua...
Source: Journal of the Saudi Heart Association - August 15, 2019 Category: Cardiology Source Type: research

Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies
ConclusionProviders serving American Indians need to be aware of the possibility of statin-associated autoimmune myopathy and familiar with its presentation. Larger, inclusive, population-based investigations are needed to elucidate risk factors for this condition, in particular the potential interactions between predisposing HLA alleles, diabetes and specific statin exposures. This is necessary to identify effective and safe lipid-lowering medications.
Source: Rheumatology - August 13, 2020 Category: Rheumatology Source Type: research

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
CONCLUSIONS: Although areas of uncertainty remain, intermittent dosing (particularly with rosuvastatin and atorvastatin) in previously intolerant patients is a useful strategy to capitalize on the benefits of this therapy. Larger scale randomized trials are necessary to more clearly define the role of this strategy and the optimal choice of regimen. PMID: 23482733 [PubMed - in process]
Source: The Annals of Pharmacotherapy - March 1, 2013 Category: Drugs & Pharmacology Authors: Keating AJ, Campbell KB, Guyton JR Tags: Ann Pharmacother Source Type: research

Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
In conclusion, RYR and CoQ10 may offer alternatives to overcome atorvastatin-associated myopathy. PMID: 24896301 [PubMed - in process]
Source: Canadian Journal of Physiology and Pharmacology - June 1, 2014 Category: Drugs & Pharmacology Authors: Abdelbaset M, Safar MM, Mahmoud SS, Negm SA, Agha AM Tags: Can J Physiol Pharmacol Source Type: research

SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population.
CONCLUSIONS In Czech patients treated with low statin doses, there is no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy. PMID: 25992810 [PubMed - in process]
Source: Medical Science Monitor - May 22, 2015 Category: Research Tags: Med Sci Monit Source Type: research

Myopathy induced by statin‑ezetimibe combination: Evaluation of potential risk factors
We report a case of myalgia with elevated serum creatinine phosphokinase in a patient after 2 months of therapy with fixed dose combination of atorvastatin and ezetimibe (10 mg each). At the time of the event, patient was undertaking moderate physical exertion in the form of brisk walking for 30–40 min a day and was detected to have low serum Vitamin D levels. The adverse event resolved after stopping atorvastatin-ezetimibe combination therapy. Potential risk factors, such as physical exertion and Vitamin D deficiency, co-existent in dyslipidemic patients, may exacerbate myopathy potential of these drugs, and ...
Source: Indian Journal of Pharmacology - September 15, 2015 Category: Drugs & Pharmacology Authors: Ballari BrahmachariSuparna Chatterjee Source Type: research

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case–Control Studies
This study aimed to investigate this genetic association. Databases of PubMed, EMBASE, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database, and Wanfang Data were searched till June 17, 2015. Case-control studies investigating the association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk were included. The Newcastle–Ottawa Scale (NOS) was used for assessing the quality of included studies. Data were pooled by odds ratios (ORs) and their 95% confidence intervals (CIs). Nine studies with 1360 cases and 3082 controls wer...
Source: Medicine - September 1, 2015 Category: Internal Medicine Tags: Research Article: Meta-Analysis of Observational Studies in Epidemiology (MOOSE Compliant) Source Type: research

Anti-HMGCR Necrotizing Autoimmune Myopathy Presenting as Acute-on-Chronic Weakness (P3.129)
CONCLUSION: We discuss a case in which a patient with anti-HMGCR necrotizing autoimmune myopathy presented with a seemingly acute worsening of a more chronic painful process and then soon afterwards had an NSTEMI likely related to rhabdomyolysis.Disclosure: Dr. Lening has nothing to disclose. Dr. Khanlou has nothing to disclose. Dr. Vitantonio has nothing to disclose. Dr. Morrill has nothing to disclose. Dr. Turetsky has nothing to disclose. Dr. Mishra has nothing to disclose. Dr. Jamal has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Lening, C., Khanlou, N., Vitantonio, D., Morrill, J., Turetsky, A., Mishra, S., Jamal, N. Tags: Acquired Muscle Disorders: Clinical and Pathological Aspects Source Type: research

Impact of pharmacogenetics on statin-induced myopathy in south Indian subjects
ConclusionOur results clearly demonstrates that the frequency of CYP3A5*3 splicing variant is higher in myopathy group as compared to tolerant group. We did not find significant association of genetic polymorphisms in CYP3A5, COQ and SLCO1B1 with atorvastatin or rosuvastatin induced myopathy.
Source: Indian Heart Journal - August 10, 2018 Category: Cardiology Source Type: research